DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Comprehensive clinical development programs being initiated for each investigational candidate
Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
The company will present 21 oral and poster presentations spanning investigational and approved therapies
The safety profile was described as manageable, though not without notable toxicities
The approval is supported by results from the Phase 3 SWOG 1826 trial
With standout ADC and t-cell engager response data across hard-to-treat cancers
BMS is moving beyond conversational AI into what it describes as “agentic” systems
The leading cancer hospital urges carrier screening to prevent thalassemia burden
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
